Search Results
You are looking at 1 - 1 of 1 items for
- Author: Zhiyong Chang x
- Refine by access: All content x
Search for other papers by Dong Li in
Google Scholar
PubMed
Search for other papers by Chenhao Cao in
Google Scholar
PubMed
Search for other papers by Zhuofan Li in
Google Scholar
PubMed
Search for other papers by Zhiyong Chang in
Google Scholar
PubMed
Search for other papers by Ping Cai in
Google Scholar
PubMed
Search for other papers by Chenxi Zhou in
Google Scholar
PubMed
Search for other papers by Jun Liu in
Google Scholar
PubMed
Search for other papers by Kaihua Li in
Google Scholar
PubMed
Search for other papers by Bin Du in
Google Scholar
PubMed
Icariside II, a flavonoid glycoside, is the main component found invivo after the administration of Herba epimedii and has shown some pharmacological effects, such as prevention of osteoporosis and enhancement of immunity. Increased levels of marrow adipose tissue are associated with osteoporosis. S100 calcium-binding protein A16 (S100A16) promotes the differentiation of bone marrow mesenchymal stem cells (BMSCs) into adipocytes. This study aimed to confirm the anti-lipidogenesis effect of Icariside II in the bone marrow by inhibiting S100A16 expression. We used ovariectomy (OVX) and BMSC models. The results showed that Icariside II reduced bone marrow fat content and inhibited BMSCs adipogenic differentiation and S100A16 expression, which correlated with lipogenesis. Overexpression of S100A16 eliminated the inhibitory effect of Icariside II on lipid formation. β-catenin participated in the regulation adipogenesis mediated by Icariside II/S100A16 in the bone. In conclusion, Icariside II protects against OVX-induced bone marrow adipogenesis by downregulating S100A16, in which β-catenin might also be involved.
